CWC
SIOX

Carolinas Wealth Consulting’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Carolinas Wealth Consulting’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-37
Closed – – 1015
2021
Q2 		$0 Hold
37
– – ﹤0.01% 1023
2021
Q1 		$0 Hold
37
– – ﹤0.01% 1014
2020
Q4 		$0 Hold
37
– – ﹤0.01% 1060
2020
Q3 		$0 Hold
37
– – ﹤0.01% 1019
2020
Q2 		$0 Buy
+37
New +$119 ﹤0.01% 729

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Carolinas Wealth Consulting's SIOX Position: Q3 2021 in Review

Carolinas Wealth Consulting sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2021, closing a stake of 37 shares.

Carolinas Wealth Consulting first reported a position in SIOX in Q2 2020 and held it in 5 quarters. The position peaked at $0 in Q2 2021. 56 funds tracked by Wall St. Rank hold SIOX as of Q3 2021.

  • Carolinas Wealth Consulting reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 37 Sio Gene Therapies Inc. Common Stock shares in Q3 2021.
  • Carolinas Wealth Consulting first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2020 and held it in 5 quarters.
  • Carolinas Wealth Consulting's Sio Gene Therapies Inc. Common Stock position peaked at $0 in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2021.

Based on Carolinas Wealth Consulting's 13F filing for Q3 2021, filed 15 Nov 2021.